Micropoint Technologies painless micro-needle injections gets 'shot in the arm' with Angel funding!

Singapore, Singapore -- Aug 07, 2012 / (http://www.myprgenie.com) -- 7th August '12, Singapore: Micropoint Technologies announced today its successful fund raising, to underpin the product development and commercialization of its revolutionary micro-needle drug delivery system. In a ratification of Singapore Inc. working at its best, SPRING funded Incubator Mercatus Capital collaborated with Angel Investor, GITP Investments, to jointly fund Micropoint's technology. The micro-needle technology was initially developed in the laboratories at A*STAR. Micropoint Technologies is a pioneer in the field of painless injections for drug delivery, and piercing of skin for blood samples. Its micro-needle technology can be applied to a whole host of biomedical applications including transdermal drug delivery, body fluid extraction and in-vitro diagnostics. Commenting on the Angel investment and Incubation, Lim Chee Yen, Founder and CEO said, "This investment has come at an opportune time for Micropoint Technologies. After years of R&D, we now have a suite of tested products that are ready to be commercialized. The financial support coupled with the incubation services is just what Micropoint needs to become a major player in this 52 Billion US dollar industry. We have been tracking some major deals which we will announce in due course" Micropoint's core technology includes manufacturing of plastic micro-needles through an injection moulding process. These micro-needles (solid or hollow) are made small in size, for easy penetration into the stratum corneum, the outermost layer of the skin, for purposes of blood sampling, one-step diagnosis as well as drug delivery. Ravindran Govindan, Chairman Mercatus Capital said, "It used to be so painful for me to see my children cry after receiving injections. Micropoint's painless injections will make those painful visits to the doctor a thing of the past! We are proud to play a part in commercializing this valuable IP, developed at A*STAR." Micropoint's micro-needles are known to be cost-efficient, eco friendly and recyclable. The manufacturing process has been designed for easy scalability.
1

Patrick De Silva, Chief Angel at GITP Investments commented, "As the lead investor, we are very excited with the potential of Micropoint's Micro-needle technology, and are pleased to be working with Mercatus Capital in this co-investment. We have complementary strengths which we will leverage on, to accelerate Micropoint's 'Go To Market' Strategy."

About Micropoint Technologies: (www.micropoint-tech.com) Micropoint Technologies Pte. Ltd is a hi-tech product development company providing innovative solutions to the medical industry, particularly for drug delivery and diagnostics applications. It was established in 2008 to commercialize the micro-needle technology that that was invented by the Founder while working in the Institute of Materials Research and Engineering (IMRE), one of the research institutes under the Agency of Science, Technology And Research, Singapore (A*STAR).

About GITP Pte Ltd: (www.gitpx.com) GITP (Global Innovations & Technology Platform) is a Singapore based Corporate Angel Investor, which invests in Startup & Seed companies in China, India, Singapore, Indonesia, Vietnam and other countries in Asia and beyond. GITP is part of Rutledge Vine Capital, which focuses on global investments. GITP is driven by a high caliber team with a combined experience of over 80 years spent in Senior Management positions in diverse sectors in IT, Mobile, Gaming, Digital Media, Hospitality & Real Estate, Consumer marketing, Oil & Gas and the Commodities space.

About Mercatus Capital Pte Ltd: (www.mercatus-capital.com) Headquartered in Singapore, Mercatus Capital is Asia's premier Angel Investor, Incubator and Business accelerator. It aims to provide early stage support to promising entrepreneurs with ideas and technology that are disruptive and paradigm shifting. With support from SPRING Singapore, Mercatus undertakes an active incubation programme to groom the top management to prepare the companies to become major players in the global market place. The portfolio has grown to over 40 promising companies at various stages of incubation covering a diverse set of industries including Healthcare, ICT, Social Media and Material Sciences.
2

For more information, please contact: Akanksha Kapoor PR & Corporate Communications Manager

Tel: +65-67767819 Email: contactus@mercatus-capital.com

Contact: Akanksha Kapoor, Phone: +65-67767819, Email: contactus@mercatus-capital.com